Table 8. Relationship between CHD4 expression and clinicopathological data of patients.

Variable	Total, n (%)	CHD4 low expression, n (%)	CHD4 high expression, n (%)	P
Gender				0.520
Male	66 (66.0)	28 (42.4)	38 (57.6)
Female	34 (34.0)	17 (50.0)	17 (50.0)
Age (years)				0.092
<64	55 (55.0)	24 (43.6)	31 (56.4)
≥64	45 (45.0)	21 (46.7)	24 (53.3)
Loss of body mass (kg)				0.105
<5	56 (56.0)	26 (46.4)	30 (53.6)
≥5	44 (44.0)	19 (43.2)	25 (56.8)
CEA (ng/mL)				3.778
≤5	56 (56.0)	30 (53.6)	26 (46.4)
>5	44 (44.0)	15 (34.1)	29 (65.9)
Serum albumin (g/L)				1.010
<35	80 (80.0)	34 (42.5)	46 (57.5)
≥35	20 (20.0)	11 (55.0)	9 (45.0)
Tumor size (cm)				5.533
<3	63 (63.0)	34 (54.0)	29 (46.0)
≥3	37 (37.0)	11 (29.7)	26 (70.3)
Differentiation of tumor				4.302
High to middle differentiation	53 (53.0)	29 (54.7)	24 (45.3)
Low differentiation	47 (47.0)	16 (34.0)	31 (66.0)
Site of tumor				0.253
High-medium	36 (36.0)	15 (41.7)	21 (58.3)
Low	64 (64.0)	30 (46.9)	34 (53.1)
TNM stage				10.725
I–II	32 (32.0)	22 (68.8)	10 (31.2)
III–IV	68 (68.0)	23 (33.8)	45 (66.2)
Depth of infiltration				0.049
In the early (Tis + T1)	21 (21.0)	9 (42.9)	12 (57.1)
Stage of progression (T2–T4)	79 (79.0)	36 (45.6)	43 (54.4)
Chemotherapy				3.093
Yes	64 (64.0)	33 (51.6)	31 (48.4)
No	36 (36.0)	12 (33.3)	24 (66.7)
Distant transfer				0.088
Yes	8 (8.0)	4 (50.0)	4 (50.0)
No	92 (92.0)	41 (44.6)	51 (55.4)
Lymph node metastasis				0.042
Yes	4 (4.0)	2 (50.0)	2 (50.0)
No	96 (96.0)	43 (44.8)	53 (55.2)
Invasion of nerve				1.584
Yes	21 (21.0)	12 (57.1)	9 (42.9)
No	79 (79.0)	33 (41.8)	46 (58.2)

CEA, carcinoembryonic antigen; TNM, tumor/lymph nodes/metastasis; CHD4, chromodomain helicase DNA binding protein 4.